Amylyx Pharmaceuticals reported Phase 3 success for avexitide (a GLP-1 receptor antagonist) in post-bariatric hypoglycemia, a rare condition marked by dangerous blood-sugar crashes after weight-loss surgery. In the pivotal trial, avexitide cut the rate of serious low blood sugar events by 55% versus placebo, exceeding the study’s prespecified 35% improvement target. The company positioned the result as a step toward the first approved therapy for PBH, with investigators highlighting clinically meaningful reductions in emergencies such as loss of consciousness or seizures. Amylyx said benefits were evident alongside improved outcomes measured with disease-specific endpoints in the study population. The Phase 3 readout also caps a pivot for Amylyx, which has been working to rebuild its pipeline after recent turbulence, with avexitide now emerging as the lead GLP-1-pathway asset. Regulatory and payer discussions will likely follow as the company prepares for the next stages after efficacy support in this setting.